Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small molecule therapeutics - Inventiva Pharma

Next Previous
Drug Profile

Research programme: small molecule therapeutics - Inventiva Pharma

Alternative Names: EHMT2 inhibitors - Inventiva Pharma; Enhancer of zeste homolog 2 inhibitors - Inventiva Pharma; euchromatic histone-lysine N-methyltransferase 2 - Inventiva Pharma; EZH2 inhibitors - Inventiva Pharma; G9a inhibitors - Inventiva Pharma; histone-lysine N-methyltransferase inhibitors - Inventiva Pharma; NSD2 inhibitors - Inventiva Pharma; TEAD/YAP inhibitors - Inventiva Pharma; YAP/TEAD inhibitors - Inventiva Pharma

Latest Information Update: 26 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inventiva Pharma
  • Developer Curie Institute; Inventiva Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors; Histone-lysine N-methyltransferase inhibitors; Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mesothelioma
  • Research Breast cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Skin cancer
  • Discontinued Respiratory tract disorders

Most Recent Events

  • 26 Jun 2024 Discontinued for Respiratory tract disorders in France (PO) (Inventiva pipeline; June 2024)
  • 24 Jun 2024 Early research is ongoing in Breast cancer, Non-small-cell-lung-cancer, Multiple myeloma, Non-Hodgkin's lymphoma, Ovarian cancer and Skin cancer in France (PO)
  • 24 Jun 2024 Preclinical development is ongoing in Mesothelioma in France (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top